drugset / Trial / NCT05756907
Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a Phase 1b/2a, open-label, adaptive-design outpatient study to assess the safety, tolerability, and PK/PD of SON-1010 in combination with atezolizumab administered to patients with advanced solid tumors (Part 1) and patients with Platinum-resistant Ovarian Cancer (Part 2)
Timeline
- Start
- 2023-09-15
- Primary completion
- 2025-12-31
- Completion
- 2026-01-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SON-1010 | Protein / enzyme biologic | — | — |
| Background | Atezolizumab | Monoclonal antibody | — | — |